Anti–tumor necrosis factor (TNF) agents, widely used in rheumatology and gastroenterology, carry some safety risks. While the risk of infection or malignancy are common concerns, neurological complications, while rare, are also possible.
Anti—tumor necrosis factor (anti-TNF) agents, widely used in rheumatology and gastroenterology, carry some safety risks. While the risk of infection or malignancy are common concerns, neurological complications, while rare, are also possible.
During the fourth congress of the European Academy of Neurology, held in Lisbon, Portugal, from June 16 to 19, researchers reported on neurological complications with anti-TNF drugs in their 16 years of experience in a tertiary university hospital in Madrid, Spain.
The researchers performed a retrospective analysis of their center’s neurology department from 2002 to 2007 and identified patients who had received the anti-TNF agents infliximab, etanercept, adalimumab, and golimumab. They included in their analysis patients who had neurological issues while actively being treated with any of these agents.
In total, there were 15 episodes of neurological complications in 14 patients who were receiving treatment with infliximab, adalimumab, or golimumab to treat inflammatory bowel disease, rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, or pyoderma gangrenosum. No patients being treated with etanercept reported neurological complications.
Nine of the patients who had complications were treated with infliximab, 6 were treated with adalimumab, and 1 was treated with golimumab.
In total:
The authors write that, in their experience, neurological complications of anti-TNF therapies are rare, but that they are most commonly reported with infliximab, and stroke is the most commonly reported complication; “A possible association with stroke of undetermined etiology should be assessed with prospective studies,” say the researchers.
Reference
Gomez A, Nater E, Monreal S, et al. Neurological complications of antiTNF therapies: 16 years of tertiary university hospital experience. Presented at the European Academy of Neurology Congress, June 16-19, 2018; Lisbon, Portugal. Abstract EPR1130. https://ipp-ean18.netkey.at/index.php?p=recorddetail&rid=2dec48c7-efbe-4a30-aa16-a7c040870eb3&t=browsepresentations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.
Patient With MS Sues J&J Over ERISA Violation
February 14th 2024After a patient with multiple sclerosis (MS) was forced to pay exorbitant out-of-pocket costs for a brand name medication when she could’ve gotten a generic for way less, the patient filed a class action complaint against her employer, Johnson & Johnson (J&J), for violating the Employee Retirement Income Security Act of 1974 (ERISA).